IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer Based on POTOMAC Phase III trial results ...
Therapeutic progress has accelerated, with multiple recent approvals improving outcomes across early-stage, muscle-invasive, and metastatic urothelial carcinoma. FGFR3 and HER2 protein expression by ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. After gaining accelerated approval in the indication in 2017, the company grudgingly clawed back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results